Iovance Biotherapeutics, Inc. (IOVA) earnings
IOVA earnings moved a median of +1.14% by the close. Quarterly and annual IOVA reports and results, each read against the price at its own news timestamp. Back to the IOVA overview →
22 measured IOVA earnings events.
Where these IOVA earnings landedvs 22 measured IOVA earnings reactions
| Middle 50% of IOVA earnings reactions | -4.69% to +4.72% |
|---|---|
| Median reaction (to close) | +1.14% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 IOVA earnings events with a measured close landed between -4.69% and +4.72%; 59% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -2.19% | +4.72% | |
| Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | Press release | -2.19% | +4.72% | |
| Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 | Press release | +2.21% | +3.53% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +9.26% | +1.14% | |
| Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates | Press release | +9.26% | +1.14% | |
| Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 | Press release | +0.14% | -0.29% | |
| Form 10-K IOVANCE BIOTHERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | +4.09% | +8.93% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -0.44% | +2.21% | |
| Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results | Press release | -0.44% | +2.21% | |
| Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 | Press release | -1.12% | +0.90% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +10.16% | +9.90% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | -3.89% | -9.33% | |
| Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 | Press release | -3.89% | -9.33% | |
| Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 | Press release | +4.27% | -0.28% | |
| Form 10-K IOVANCE BIOTHERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.65% | +8.04% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -1.40% | -1.17% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +0.64% | +5.64% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | -12.27% | -15.91% | |
| Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates | Press release | -12.27% | -15.91% | |
| Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 | Press release | +2.03% | +6.38% | |
| Form 10-K IOVANCE BIOTHERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.21% | -5.86% | |
| Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | +3.15% | -7.13% |
Keep exploring
More IOVA: analyst actions → · SEC filings → · IOVA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EXPRESS SCRIPTS (ESRX) | 1,137 | +0.02% | 51% |
| Neovasc Inc. - Common Shares (NVCN) | 1,136 | -0.47% | 37% |
| iRhythm Holdings, Inc. (IRTC) | 1,114 | -0.12% | 46% |
| GENOMIC HEALTH (GHDX) | 1,111 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.